Renée Turzanski Fortner1, Antje Damms-Machado1, Rudolf Kaaks2. 1. Division of Cancer Epidemiology, German Cancer Research Center (DFKZ), Heidelberg, Germany. 2. Division of Cancer Epidemiology, German Cancer Research Center (DFKZ), Heidelberg, Germany. Electronic address: r.kaaks@dkfz.de.
Abstract
OBJECTIVES: Tumor-associated autoantibodies (AAbs), produced as an immune response to tumor-associated antigens (TAAs), are a novel pathway of early detection markers. METHODS: We conducted a systematic review on AAbs and ovarian cancer to summarize the diagnostic performance of individual AAbs and AAb panels. A total of 29 studies including 85 AAbs were included; 27 of the studies were conducted in prevalent cases and cancer-free controls and 2 investigations included pre-diagnosis samples. The majority of studies were hypothesis-driven, evaluating AAbs to target TAAs; 10 studies used screening approaches such as serological expression cloning (SEREX) and nucleic acid-programmable protein arrays (NAPPA). RESULTS: The highest sensitivities for individual AAbs were reported for RhoGDI-AAbs (89.5%) and TUBA1C-AAbs (89%); however, specificity levels were relatively low (80% and 75%, respectively). High sensitivities at high specificities were reported for HOXA7-AAbs for detection of moderately differentiated ovarian tumors (66.7% sensitivity at 100% specificity) and IL8-AAbs in stage I-II ovarian cancer (65.5% sensitivity at 98% specificity). A panel of 11 AAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) provided 45% sensitivity at 98% specificity for serous ovarian cancer, when at least 2 AAbs were above a threshold of 95% specificity. Twelve of the AAbs identified in this review were investigated in more than one study. Data on diagnostic discrimination by tumor histology and stage at diagnosis are sparse. Limited data suggest select AAb markers improve diagnostic discrimination when combined with markers such as CA125 and HE4. CONCLUSIONS: AAbs for ovarian cancer early detection is an emerging area, and large-scale, prospective investigations considering histology and stage are required for discovery and validation. However, data to date suggests panels of AAbs may eventually reach sufficient diagnostic discrimination to allow earlier detection of disease as a complement to existing markers and transvaginal ultrasound.
OBJECTIVES:Tumor-associated autoantibodies (AAbs), produced as an immune response to tumor-associated antigens (TAAs), are a novel pathway of early detection markers. METHODS: We conducted a systematic review on AAbs and ovarian cancer to summarize the diagnostic performance of individual AAbs and AAb panels. A total of 29 studies including 85 AAbs were included; 27 of the studies were conducted in prevalent cases and cancer-free controls and 2 investigations included pre-diagnosis samples. The majority of studies were hypothesis-driven, evaluating AAbs to target TAAs; 10 studies used screening approaches such as serological expression cloning (SEREX) and nucleic acid-programmable protein arrays (NAPPA). RESULTS: The highest sensitivities for individual AAbs were reported for RhoGDI-AAbs (89.5%) and TUBA1C-AAbs (89%); however, specificity levels were relatively low (80% and 75%, respectively). High sensitivities at high specificities were reported for HOXA7-AAbs for detection of moderately differentiated ovarian tumors (66.7% sensitivity at 100% specificity) and IL8-AAbs in stage I-II ovarian cancer (65.5% sensitivity at 98% specificity). A panel of 11 AAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) provided 45% sensitivity at 98% specificity for serous ovarian cancer, when at least 2 AAbs were above a threshold of 95% specificity. Twelve of the AAbs identified in this review were investigated in more than one study. Data on diagnostic discrimination by tumor histology and stage at diagnosis are sparse. Limited data suggest select AAb markers improve diagnostic discrimination when combined with markers such as CA125 and HE4. CONCLUSIONS: AAbs for ovarian cancer early detection is an emerging area, and large-scale, prospective investigations considering histology and stage are required for discovery and validation. However, data to date suggests panels of AAbs may eventually reach sufficient diagnostic discrimination to allow earlier detection of disease as a complement to existing markers and transvaginal ultrasound.
Authors: Frank Antony; Cecilia Deantonio; Diego Cotella; Maria Felicia Soluri; Olga Tarasiuk; Francesco Raspagliesi; Fulvio Adorni; Silvano Piazza; Yari Ciani; Claudio Santoro; Paolo Macor; Delia Mezzanzanica; Daniele Sblattero Journal: Oncoimmunology Date: 2019-06-04 Impact factor: 8.110
Authors: Chih-Wei Lin; Jia Xie; Ding Zhang; Kyung Ho Han; Geramie Grande; Nicholas C Wu; Zhuo Yang; Kyungmoo Yea; Richard A Lerner Journal: Proc Natl Acad Sci U S A Date: 2019-12-23 Impact factor: 11.205
Authors: Rudolf Kaaks; Renée Turzanski Fortner; Anika Hüsing; Myrto Barrdahl; Marika Hopper; Theron Johnson; Anne Tjønneland; Louise Hansen; Kim Overvad; Agnès Fournier; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Laure Dossus; Mattias Johansson; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Sabina Sieri; Amalia Mattiello; Domenico Palli; Rosario Tumino; Giuseppe Matullo; N Charlotte Onland-Moret; Inger T Gram; Elisabete Weiderpass; Maria-Jose Sánchez; Carmen Navarro Sanchez; Eric J Duell; Eva Ardanaz; Nerea Larranaga; Eva Lundin; Annika Idahl; Karin Jirström; Björn Nodin; Ruth C Travis; Elio Riboli; Melissa Merritt; Dagfinn Aune; Kathryn Terry; Daniel W Cramer; Karen S Anderson Journal: Int J Cancer Date: 2018-03-08 Impact factor: 7.396
Authors: Laura C Hurley; Nancy K Levin; Madhumita Chatterjee; Jasmine Coles; Shlomo Muszkat; Zachary Howarth; Gregory Dyson; Michael A Tainsky Journal: Cancer Biomark Date: 2020 Impact factor: 4.388
Authors: Wei-Lei Yang; Zhen Lu; Jing Guo; Bryan M Fellman; Jing Ning; Karen H Lu; Usha Menon; Makoto Kobayashi; Samir M Hanash; Joseph Celestino; Steven J Skates; Robert C Bast Journal: Cancer Date: 2019-11-12 Impact factor: 6.860
Authors: Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-13 Impact factor: 4.254